These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 21469915)
21. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558 [TBL] [Abstract][Full Text] [Related]
22. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696 [TBL] [Abstract][Full Text] [Related]
23. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers. Henk HJ; Kaura S J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786 [TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective. Delea TE; Rotter J; Taylor M; Chandiwana D; Bains M; El Ouagari K; Kaura S; Morgan GJ J Med Econ; 2012; 15(3):454-64. PubMed ID: 22316275 [TBL] [Abstract][Full Text] [Related]
25. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Carter JA; Botteman MF Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):425-37. PubMed ID: 22540167 [TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid. Saad F; Segal S; Eastham J Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317 [TBL] [Abstract][Full Text] [Related]
27. The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. Akehurst R; Brereton N; Ariely R; Lusa T; Groot M; Foss P; Boonen S J Med Econ; 2011; 14(1):53-64. PubMed ID: 21222506 [TBL] [Abstract][Full Text] [Related]
28. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases. Henk HJ; Kaura S; Teitelbaum A J Med Econ; 2012; 15(1):195-204. PubMed ID: 22175657 [TBL] [Abstract][Full Text] [Related]
29. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218 [TBL] [Abstract][Full Text] [Related]
30. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Saad F Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243 [TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804 [TBL] [Abstract][Full Text] [Related]
33. Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events. Sherer JT; Adamus AT Pharmacotherapy; 2007 Feb; 27(2):207-17. PubMed ID: 17253911 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033 [TBL] [Abstract][Full Text] [Related]
35. Optimal management of metastatic bone disease. Major P Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294 [TBL] [Abstract][Full Text] [Related]
36. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma? Morgan GJ Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S24-30. PubMed ID: 21353177 [TBL] [Abstract][Full Text] [Related]
37. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ J Clin Oncol; 2003 Aug; 21(16):3150-7. PubMed ID: 12915606 [TBL] [Abstract][Full Text] [Related]
38. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071 [TBL] [Abstract][Full Text] [Related]
39. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population. Velde NV; Wu EQ; Guo A; Lu M; Yu AP; Sharma H; Liu J; Fan CP; Shi L Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):79-84. PubMed ID: 21173792 [TBL] [Abstract][Full Text] [Related]
40. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]